‌$荃信生物-B(0_老虎社区_美港股上老虎

‌$荃信生物-B(02509)$ ‌公司IL-17A抑制剂即将进入III期临床，双抗平台技术获高盛研报重点提示差异化优势，继续跟进公司发展

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":427141058351208,"tweetId":"427141058351208","gmtCreate":1745306117418,"gmtModify":1745306118937,"author":{"id":3564011840073775,"idStr":"3564011840073775","authorId":3564011840073775,"authorIdStr":"3564011840073775","name":"六一玖中路","avatar":"https://static.tigerbbs.com/a37cb08394c3dc27fb59f07921d7c74f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>‌<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ &nbsp;</a>‌<span>公司IL-17A抑制剂即将进入III期临床，双抗平台技术获高盛研报重点提示差异化优势，继续跟进公司发展</span></body></html>","htmlText":"<html><head></head><body>‌<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ &nbsp;</a>‌<span>公司IL-17A抑制剂即将进入III期临床，双抗平台技术获高盛研报重点提示差异化优势，继续跟进公司发展</span></body></html>","text":"‌$荃信生物-B(02509)$ ‌公司IL-17A抑制剂即将进入III期临床，双抗平台技术获高盛研报重点提示差异化优势，继续跟进公司发展","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/427141058351208","repostId":0,"isVote":1,"tweetType":1,"viewCount":426,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02509"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":112,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/427141058351208"}